134 related articles for article (PubMed ID: 37769430)
1. Prevalence of 2-year "No evidence of disease activity" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study.
Bazzurri V; Fiore A; Curti E; Tsantes E; Franceschini A; Granella F
Mult Scler Relat Disord; 2023 Nov; 79():105015. PubMed ID: 37769430
[TBL] [Abstract][Full Text] [Related]
2. Inclusion of the Symbol Digit Modalities Test in a revised assessment of 'no evidence of disease activity-4 (NEDA-4)' in Latin-American patients with multiple sclerosis.
Guevara C; Villa E; Diaz V; Garrido C; Martinez M; Orellana P; Alarcón P; Silva-Rosas C; Barker GJ; Kempton MJ; de Grazia J
Mult Scler Relat Disord; 2020 Jul; 42():102076. PubMed ID: 32361478
[TBL] [Abstract][Full Text] [Related]
3. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
Zafar A; AlShamrani FJG
Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
[TBL] [Abstract][Full Text] [Related]
4. Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
Newsome SD; Scott TF; Arnold DL; Altincatal A; Naylor ML
Mult Scler Relat Disord; 2022 Jan; 57():103367. PubMed ID: 35158473
[TBL] [Abstract][Full Text] [Related]
5. No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany.
Huhn K; Senger D; Utz KS; Schmidt M; Fröhlich K; Waschbisch A; Seifert F; Dörfler A; Lee DH; Linker RA
Mult Scler Relat Disord; 2019 Jan; 27():133-138. PubMed ID: 30384198
[TBL] [Abstract][Full Text] [Related]
6. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
[TBL] [Abstract][Full Text] [Related]
7. Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis.
Tsantes E; Curti E; Collura F; Bazzurri V; Fiore A; Granella F
J Neurol Sci; 2020 Jul; 414():116827. PubMed ID: 32289575
[TBL] [Abstract][Full Text] [Related]
8. Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice.
Guevara C; Garrido C; Martinez M; Farias GA; Orellana P; Soruco W; Alarcón P; Diaz V; Silva C; Kempton MJ; Barker G; de Grazia J
Front Neurol; 2019; 10():788. PubMed ID: 31396148
[No Abstract] [Full Text] [Related]
9. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Kappos L; De Stefano N; Freedman MS; Cree BA; Radue EW; Sprenger T; Sormani MP; Smith T; Häring DA; Piani Meier D; Tomic D
Mult Scler; 2016 Sep; 22(10):1297-305. PubMed ID: 26585439
[TBL] [Abstract][Full Text] [Related]
10. Plasma neurofilament light chain levels are predictors of disease activity in multiple sclerosis as measured by four-domain NEDA status, including brain volume loss.
Szilasiová J; Mikula P; Rosenberger J; Fedičová M; Gdovinová Z; Urban P; Frigová L
Mult Scler; 2021 Nov; 27(13):2023-2030. PubMed ID: 33635154
[TBL] [Abstract][Full Text] [Related]
11. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.
Rotstein DL; Healy BC; Malik MT; Chitnis T; Weiner HL
JAMA Neurol; 2015 Feb; 72(2):152-8. PubMed ID: 25531931
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic inertia in relapsing-remitting multiple sclerosis.
Rodrigues R; Rocha R; Bonifácio G; Ferro D; Sabença F; Gonçalves AI; Correia F; Pinheiro J; Loureiro JL; Guerreiro RP; Vale J; Sá MJ; Costa A
Mult Scler Relat Disord; 2021 Oct; 55():103176. PubMed ID: 34343868
[TBL] [Abstract][Full Text] [Related]
14. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
Prosperini L; Annovazzi P; Boffa L; Buscarinu MC; Gallo A; Matta M; Moiola L; Musu L; Perini P; Avolio C; Barcella V; Bianco A; Farina D; Ferraro E; Pontecorvo S; Granella F; Grimaldi LME; Laroni A; Lus G; Patti F; Pucci E; Pasca M; Sarchielli P;
J Neurol; 2018 Dec; 265(12):2851-2860. PubMed ID: 30259178
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
Vermersch P; Oreja-Guevara C; Siva A; Van Wijmeersch B; Wiendl H; Wuerfel J; Buffels R; Kadner K; Kuenzel T; Comi G;
Eur J Neurol; 2022 Mar; 29(3):790-801. PubMed ID: 34748672
[TBL] [Abstract][Full Text] [Related]
16. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
Zanetta C; Rocca MA; Meani A; Martinelli V; Ferrè L; Moiola L; Filippi M
J Neurol; 2023 Jul; 270(7):3553-3564. PubMed ID: 37027018
[TBL] [Abstract][Full Text] [Related]
18. Self-injectable DMTs in relapsing MS: NEDA assessment at 10 years in a real-world cohort.
Ozakbas S; Piri Cinar B; Baba C; Kosehasanogullari G; Sclerosis Research Group M
Acta Neurol Scand; 2022 May; 145(5):557-564. PubMed ID: 35043388
[TBL] [Abstract][Full Text] [Related]
19. Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis.
Rotstein D; Solomon JM; Sormani MP; Montalban X; Ye XY; Dababneh D; Muccilli A; Saab G; Shah P
Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36224046
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
Perumal J; Balabanov R; Su R; Chang R; Balcer L; Galetta S; Campagnolo DI; Avila R; Lee L; Rutledge D; Fox RJ
Adv Ther; 2021 Jul; 38(7):3724-3742. PubMed ID: 34014549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
